Fairmount Funds Management LLC
About Fairmount Funds Management LLC’s 13F portfolio
Fairmount Funds Management LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Fairmount Funds Management LLC reported $1.5B across 12 US-listed positions (). Its largest position is ORUKA THERAPEUTICS INC (ORKA) at 23% of the reported book, and its ten biggest holdings make up 98% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | $97.57 +1.91% | 23% | 3.7M | $352.6M |
| 2 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | $84.83 +1.01% | 16% | 2.5M | $247.3M |
| 3 | NASDAQ: DMRA DAMORA THERAPEUTICS INC | — — | 15% | 8.7M | $226.6M |
| 4 | NASDAQ: COGT COGENT BIOSCIENCES INC | $27.74 −0.25% | 14% | 5.5M | $213.0M |
| 5 | NASDAQ: JBIO JADE BIOSCIENCES INC | $15.06 −2.78% | 6.7% | 4.6M | $101.2M |
| 6 | NASDAQ: ELVN ENLIVEN THERAPEUTICS INC | $46.41 +3.39% | 6.2% | 1.9M | $94.2M |
| 7 | NASDAQ: VRDN VIRIDIAN THERAPEUTICS INC | $31.44 +4.38% | 6.2% | 5.1M | $93.5M |
| 8 | NASDAQ: ZBIO ZENAS BIOPHARMA INC | $25.04 −5.22% | 4.0% | 2.4M | $59.9M |
| 9 | NASDAQ: CBIO CRESCENT BIOPHARMA INC. | $12.91 +4.11% | 3.3% | 2.7M | $49.5M |
| 10 | NASDAQ: APGE APOGEE THERAPEUTICS INC | $135.07 0.00% | 2.6% | 299K | $39.6M |
| 11 | NASDAQ: SNSE FAETH THERAPEUTICS INC | $25.96 −28.23% | 1.2% | 722K | $18.1M |
| 12 | NASDAQ: IKT INHIBIKASE THERAPEUTICS INC | $1.30 −5.80% | 1.2% | 8.6M | $17.5M |
Showing the 12 largest positions reported in this 13F.
- Healthcare85%
- AddedVRDNVIRIDIAN THERAPEUTICS INC+30.1%$93.5M
- NewSNSEFAETH THERAPEUTICS INC—$18.1M
- SoldSYRESPYRE THERAPEUTICS INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | ORKA ORUKA THERAPEUTICS, INC. | 13D | 20.0% · 2 classes | 11.2M | Filed 19 SEP 2025 |
| 2 | DMRA Galecto, Inc. | 13D | 20.0% | 8.7M | Filed 11 FEB 2026 |
| 3 | APGE Apogee Therapeutics, Inc. | 13D | 10.0% | 6.0M | Filed 22 JAN 2026 |
Showing all 3 disclosed stakes. 1 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Fairmount Funds Management LLC’s 13F portfolio
Fairmount Funds Management LLC’s $1.5B 13F book is spread across 12 reported positions and is highly concentrated — its ten largest positions alone are 98% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are ORKA, DNTH, DMRA, COGT and JBIO, led by ORUKA THERAPEUTICS INC (ORKA) at 23% of the portfolio. The heaviest sector exposure is Healthcare (85%).
What Fairmount Funds Management LLC changed last quarter
Between 2026-03-31 and Q2 2026, Fairmount Funds Management LLC was a net buyer: it opened 1 new positions and added to 1 more, while trimming 0 and closing 1 outright. Against a 12-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was VIRIDIAN THERAPEUTICS INC (VRDN), and its biggest reduction was SPYRE THERAPEUTICS INC (SYRE).
What a 13F does and doesn’t reveal
A 13F captures only Fairmount Funds Management LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Fairmount Funds Management LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Fairmount Funds Management LLC's profile on this page is built directly from those filings.
How current is the 13F data on Fairmount Funds Management LLC's page?
It reflects Fairmount Funds Management LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Fairmount Funds Management LLC files its next quarterly report, this page refreshes automatically.
Can I see Fairmount Funds Management LLC's complete list of holdings?
This page highlights Fairmount Funds Management LLC's largest positions rather than all 12 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Fairmount Funds Management LLC's filings.
Does a 13F show everything Fairmount Funds Management LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Fairmount Funds Management LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Fairmount Funds Management LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

